parallel plate flow chamber. The WSS in these devices is usually steady because of difficulties in simulating pulsatile flow. Cyclic straining devices provide only strain, by stretching cells on a compliant membrane without flow. Both types of systems are thus limited by their design. However, no studies have been performed studying both parameters (WSS and CS) using cells grown on a single type of support surface because such a system, until now, has remained technologically unfeasible. The present invention addresses and solves this long-felt need by providing a system in which endothelial cells can be grown on a single support surface, and subjected to studies in which both wall shear stress and circumferential strain can be examined independently of each other.—

Please replace the paragraph beginning at page 10, line 18, with the following rewritten paragraph:

hemodynamic simulation comprising a vessel having properties of a blood vessel, a reservoir containing a quantity of fluid, tubing connecting the vessel and reservoir, and at least one pump for circulating the fluid within the system. Fluid can be tissue culture medium or blood analog fluid, and the vessel may include mammalian cells attached to its inside. A drive system, comprising two reciprocating drive shafts that are coupled by a cam, enables the uncoupling of pulsatile flow and pulsatile pressure to provide independent control over wall shear stress and circumferential strain. The shaft drives two pumps that are 180 degrees out-of-phase and are connected upstream and downstream of the vessel, and effect this uncoupling.—

Please replace the paragraph beginning at page 15, line 18, with the

following rewritten paragraph:

--Each of pumps 40 and 42 is under the control of a drive system unit 44, which comprises a plurality of independent linear actuators 46. These actuators 46 can be individual, stand alone units, for may be controlled by one or more computer systems 48. In the embodiment in Fig. 1A, the second pumps 40 are connected by a shaft 50, and the third pumps 42 are connected by a second shaft 52. In one embodiment of the present invention, in which a 4-bar linkage mechanism is the drive system, a cam 54 affects the control of the various second pumps 40 and third pumps 42. In one embodiment of the present invention (Fig. 1B) the drive system unit 44 comprises six computer-controlled linear actuators, while in another embodiment (Fig. 1A) the drive system unit 44 comprises four independent computer-controlled linear actuators.--

Please replace the paragraph beginning at page 14, line 1, with the following rewritten paragraph:

--A pressure sensor 18 is used for monitoring the internal system pressure, and positioned either upstream and/or downstream of the compliant vessel 12. A pressure sensor can also be placed in the external chamber 36 to monitor external chamber pressure. Pressure sensor 18 can also be a blood pressure catheter (such as, for example, and not intended as a limitation, a MILLAR® catheter (MPC-500 with pressure meter TCB500; Registered Trademark of Millar Instruments Corp,, Houston TX), in either a fluid contacting or non-contacting version. Pressure sensor 18 may also be a pressure probe, such as those known to those skilled in the art. In one embodiment of the present invention, the pressure sensor is a catheter tip transducer

(Millar) which is inserted upstream into the lumen of the compliant vessel. Where cells are being used in the compliant vessel 12, the pressure sensor 18 is kept upstream to avoid damaging the cells. Pressure drop across the compliant vessel has been shown to be negligible.--

Please replace the paragraph beginning at page 23, line 28, with the following rewritten paragraph:

--In this example, the vessel chosen for growth of endothelial cells is a silicone tubing, sold by Dow-Corning, Midland, MI under the brand name of SYLGARD 184® elastomer, or Silastic (MDX4-4210), Medical Grade tubing, and used to prepare elastic artery models. These models were prepared using the method described by Lee and Tarbell (1997, and hereby incorporated by reference), and included the preparation of models of human linear and bifurcating arteries.--

Please replace the paragraph beginning at page 25, line 17, with the following rewritten paragraph:

--Requirements of the fluid 16 include having a viscosity that can be elevated to achieve conditions of physiologic stress at modest flow rates. Dextran is used within the fluid while the present invention uses vessels of approximately 0.79 cm diameter; in instances employing vessels of smaller diameter, addition of dextran is not necessary. The fluid should be free of Phenol Red and serum so as not to interfere with measurements of other cellular products, such as prostacycline or nitric oxide. Serum and other substances can be added to the media if these substances are under study, or if the serum or substance is required by the cell line.--

Please replace the paragraph beginning at page 27, line 35, with the following rewritten paragraph:

3 **4**

5

7

8

9

10

11

12

13

14

15

16

17 18

19

20

21

22

23

1

2

--Example 1 described the use of vessel models, modeled after the structure and material properties of actual human aortic vessels. In addition to using models of vessels, other vessels can be used in conjunction with the present invention. These can be chosen from the group consisting of an artery, an artificial artery, a vein, human umbilical tissue, or a non-rigid tube. The artery may comprise a bovine aorta, or a human coronary artery. The vein may comprise bovine veins, or human veins such as a human leg vein or a human umbilical vein. Bovine tissue can be obtained sources, such as Vec commercial supply from Technologies, Ithaca NY and human umbilical materials can be obtained a local hospital, or a commercial sources such as Clonetics, Vec Technologies, or other sources known to those skilled in the art. In addition to studying the effects of hemodynamic conditions on endothelial cells, other types of cells can also be used, including smooth muscle cells, cartilage cells, osteocytes, embryonic and adult stem cells, and the like.--

2425

In the Claims:

262728

Please amend Claims 2-4, inclusive, and Claim 6.

29 30

Please add Claims 7-53, inclusive.

3132

2. (Amended) The system as described in claim 11, wherein the vessel preferably is a model of a mammalian blood vessel.

3435

36

33

3. (Amended) The system as described in claim 11, wherein the vessel is biocompatible.